Fundamentals · JNJ
Valuation Summary for JNJ
AI-generated plain-English read of valuation summary for JNJ. Updated daily.
Rich multiples, expanding
moderateRich multiples (29.5x) with expanding trajectory: multiples pricing in growth acceleration; any miss compresses sharply.
What will probably happen
- Expanding multiples on an already-expensive stock implies the market expects earnings acceleration; any miss triggers sharp compression.
- Modest income yield provides a partial floor while waiting for valuation normalisation.
What to do
- If you HOLD this stock
- You're long expensive multiples that are still expanding, which implies the market is pricing in continued growth acceleration. Any disappointment compresses sharply. Hold but trim if the next 2 quarters miss.
- If you're EVALUATING this stock
- Pass unless your conviction on growth durability is high. Expanding multiples already price in the bull case: you're paying for a scenario that hasn't happened yet.
- If you trade OPTIONS
- Sell premium against shares (covered calls); IV likely elevated. Avoid long calls: multiple compression risk dominates if growth disappoints. Bear call spreads hedge the downside.
10 quarters / 3 populated multiples: directionally informative; use more data for full conviction.
Technical details
Technical analysis
- P/Book
- 7.3x
- P/Sales
- 6.3x
- EV/EBITDA
- --
- FCF yield
- --
- EV/Revenue
- --
- P/E (forward)
- --
- Dividend yield
- 2.0%
- Earnings yield
- --
- Income profile
- Balanced Income
- P/E (trailing)
- 29.5x
- Sector context
- Pharmaceuticals
- Sector comparison
- Unknown Vs Sector
- Absolute valuation
- Richly Valued
- History (quarters)
- 10
- Multiple trajectory
- Expanding
Key levels
| Level | Value |
|---|---|
| pb ratio | 7.293 |
| pe ratio | 29.458 |
| ps ratio | 6.328 |
| n quarters | 10 |
| current price | 285.75 |
| prior year pe | 16.306 |
| dividend yield | 0.02 |
Caveats
- Multiples should be read alongside growth and quality metrics: a low P/E on declining earnings isn't cheap, it's a value trap warning.
- Sector context wasn't provided; absolute multiples may mislead without industry comparison.